JP2004501190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501190A5 JP2004501190A5 JP2002504995A JP2002504995A JP2004501190A5 JP 2004501190 A5 JP2004501190 A5 JP 2004501190A5 JP 2002504995 A JP2002504995 A JP 2002504995A JP 2002504995 A JP2002504995 A JP 2002504995A JP 2004501190 A5 JP2004501190 A5 JP 2004501190A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- therapeutic agent
- gastric
- pharmaceutical dosage
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 49
- 239000003814 drug Substances 0.000 claims 43
- 229940124597 therapeutic agent Drugs 0.000 claims 38
- 230000002496 gastric effect Effects 0.000 claims 32
- 239000002245 particle Substances 0.000 claims 32
- 210000004051 gastric juice Anatomy 0.000 claims 31
- 210000002784 stomach Anatomy 0.000 claims 24
- 239000013028 medium composition Substances 0.000 claims 23
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 21
- 229960001344 methylphenidate Drugs 0.000 claims 21
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims 15
- 239000001263 FEMA 3042 Substances 0.000 claims 15
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims 15
- 239000000017 hydrogel Substances 0.000 claims 15
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims 15
- 229940033123 tannic acid Drugs 0.000 claims 15
- 235000015523 tannic acid Nutrition 0.000 claims 15
- 229920002258 tannic acid Polymers 0.000 claims 15
- 239000011159 matrix material Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 238000000576 coating method Methods 0.000 claims 11
- 239000011248 coating agent Substances 0.000 claims 10
- 230000014759 maintenance of location Effects 0.000 claims 10
- 239000002775 capsule Substances 0.000 claims 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 5
- 239000000853 adhesive Substances 0.000 claims 5
- 230000001070 adhesive effect Effects 0.000 claims 5
- 229960004502 levodopa Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000000717 retained effect Effects 0.000 claims 5
- 239000012530 fluid Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 229960004205 carbidopa Drugs 0.000 claims 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- -1 superdisintegrant Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010027336 Menstruation delayed Diseases 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 239000002077 nanosphere Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21383200P | 2000-06-23 | 2000-06-23 | |
| US21711000P | 2000-07-10 | 2000-07-10 | |
| US22321200P | 2000-08-04 | 2000-08-04 | |
| PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501190A JP2004501190A (ja) | 2004-01-15 |
| JP2004501190A5 true JP2004501190A5 (enExample) | 2005-02-17 |
Family
ID=27395915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504995A Pending JP2004501190A (ja) | 2000-06-23 | 2001-06-22 | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1305021A4 (enExample) |
| JP (1) | JP2004501190A (enExample) |
| KR (1) | KR20030013460A (enExample) |
| AU (2) | AU2001268722B8 (enExample) |
| CA (1) | CA2412490A1 (enExample) |
| CZ (1) | CZ2003199A3 (enExample) |
| EA (1) | EA200300046A1 (enExample) |
| HU (1) | HUP0301465A3 (enExample) |
| IL (1) | IL153497A0 (enExample) |
| MX (1) | MXPA02012793A (enExample) |
| WO (1) | WO2002000213A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
| EP1416914A1 (en) * | 2001-08-16 | 2004-05-12 | The State of Oregon acting by and through The State Board of Higher Education on behalf of Oregon State University | Expandable gastric retention device |
| BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| ES2278314T3 (es) * | 2003-04-17 | 2007-08-01 | Jallal Messadek | Formulaciones orales para la liberacion controlada de la betaina. |
| KR100894465B1 (ko) * | 2003-10-20 | 2009-04-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 레보도파의 지속적 효과를 위한 조성물 및 제형 |
| JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
| TW200533391A (en) | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
| FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
| WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
| CN101180073A (zh) | 2005-04-27 | 2008-05-14 | 贾拉尔·梅萨德克 | 胰岛素组合 |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| EP1872775A1 (en) * | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| AR062659A1 (es) * | 2006-09-08 | 2008-11-26 | Drug Tech Corp | Composicion de liberacion sostenida de levodopa y metodo para su uso |
| BRPI0622039B1 (pt) * | 2006-09-26 | 2020-11-10 | Plensat, Llc | dispositivos gástricos ingeríveis de qualidade alimentícia |
| JPWO2008087882A1 (ja) | 2007-01-15 | 2010-05-06 | キッセイ薬品工業株式会社 | 胃内滞留型レボドパ徐放性製剤 |
| KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
| DE102007026037A1 (de) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
| EP2192892A2 (en) * | 2007-07-27 | 2010-06-09 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
| CN102076215A (zh) | 2008-06-30 | 2011-05-25 | 托卡根公司 | 5-氟胞嘧啶制剂及其用途 |
| ES2740360T3 (es) * | 2008-08-15 | 2020-02-05 | Assertio Therapeutics Inc | Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC |
| CN102238946B (zh) * | 2008-11-07 | 2014-11-26 | 株式会社三养生物制药 | 用于哌醋甲酯的控制释放的药物组合物 |
| EP2661262B1 (en) * | 2011-01-06 | 2017-11-15 | Mahmut Bilgic | Improved bisphosphonate formulations |
| CN103385871B (zh) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | 复方左旋多巴微囊漂浮片 |
| EP2858604B1 (en) | 2012-06-07 | 2024-02-21 | Epitomee Medical Ltd | Expanded device |
| WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
| JP6204141B2 (ja) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | 口腔内速崩壊性固形製剤用組成物 |
| WO2014176389A1 (en) * | 2013-04-24 | 2014-10-30 | Temple University - Of The Commonwealth System Of Higher Education | Solid dosage form containing arabinogalactan |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| ES2823000T3 (es) | 2013-10-07 | 2021-05-05 | Impax Laboratories Llc | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas |
| CA2932574C (en) * | 2013-12-05 | 2023-03-07 | Tulip Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
| WO2016138440A1 (en) * | 2015-02-27 | 2016-09-01 | Cingulate Therapeutics LLC | Tripulse release stimulant formulations |
| JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
| US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
| US10918597B2 (en) * | 2017-06-16 | 2021-02-16 | Kashiv Specialty Pharmaceuticals, Llc | Gastroretentive dosage forms for sustained drug delivery |
| DK3824881T3 (da) | 2018-06-18 | 2022-05-09 | Amneal Complex Products Res Llc | Sammensætning omfattende pyridostigminbromid med forlænget frigivelse |
| EP3970701B1 (en) | 2018-06-27 | 2025-05-07 | Amneal Complex Products Research LLC | Self-regulating osmotic gastroretentive drug delivery systems |
| JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| WO2020264092A1 (en) * | 2019-06-26 | 2020-12-30 | Celista Pharmaceuticals Llc | Atomoxetine hydrochloride extended release compositions and methods of use |
| JP7624750B2 (ja) * | 2020-03-02 | 2025-01-31 | クラフト ヘルス プライベート リミテッド | 持続的薬物放出のための経口剤形 |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| JP2024501235A (ja) | 2020-12-22 | 2024-01-11 | アムニール ファーマスーティカルズ エルエルシー | レボドパ投薬レジメン |
| US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| BR9811478A (pt) * | 1997-07-23 | 2000-08-15 | Perio Prod Ltd | Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral |
-
2001
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/hu unknown
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/ja active Pending
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/es not_active Application Discontinuation
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/ko not_active Ceased
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en not_active Ceased
- 2001-06-22 IL IL15349701A patent/IL153497A0/xx unknown
- 2001-06-22 AU AU6872201A patent/AU6872201A/xx active Pending
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/cs unknown
- 2001-06-22 EA EA200300046A patent/EA200300046A1/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501190A5 (enExample) | ||
| Prinderre et al. | Advances in gastro retentive drug-delivery systems | |
| AU2001268722B8 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| US7674480B2 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| Dehghan et al. | Gastroretentive drug delivery systems: A patent perspective | |
| Nikam et al. | Eudragit a versatile polymer: a review | |
| AU2001268722A1 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| Shashank et al. | Approaches to increase the gastric residence time: floating drug delivery systems-a review | |
| JP2011518148A (ja) | カルビドパ／レボドパ胃内滞留性薬物供給 | |
| JP2008519070A5 (enExample) | ||
| JP2006505566A5 (enExample) | ||
| JP2012518655A5 (enExample) | ||
| PL129290B1 (en) | Method of obtaining new forms of dipyridamole exhibiting prolonged action | |
| JPH09316005A (ja) | 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤 | |
| JP2004501186A (ja) | アレンドロン酸塩及び／又はその他のビスホスホン酸塩の遅延型胃内放出のための組成物及び製剤 | |
| FR2830447A1 (fr) | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques | |
| JP2000508673A (ja) | イバンドロネートを含む経口薬理製剤 | |
| KR20070098823A (ko) | 복합 마이크로캡슐 형태의, 적어도 하나의 활성 성분의조절된 방출을 위한 경구용 약제 | |
| JP2007119479A5 (enExample) | ||
| PL207776B1 (pl) | Kompozycja farmaceutyczna o zmodyfikowanym uwalnianiu | |
| JP2008520736A5 (enExample) | ||
| JP2011500553A (ja) | ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤 | |
| CN109985016B (zh) | 一种非布司他的控释组合物及其制备方法 | |
| JP2008519069A5 (enExample) | ||
| CN101146521A (zh) | 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统 |